Narcolepsy Type 1 Clinical Trials and Treatments

Narcolepsy type 1 (NT1) is a chronic neurologic disorder caused by selective loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus, resulting in pathologically low cerebrospinal fluid (CSF) hypocretin-1 levels (typically <110 pg/mL). The presenting symptom complex includes excessive daytime sleepiness (EDS) with overwhelming sleep tendency, cataplexy (sudden loss of voluntary muscle tone triggered by emotional stimuli such as laughter or surprise), sleep paralysis upon awakening or sleep onset, and hypnagogic or hypnopompic hallucinations. The pathophysiology appears autoimmune, supported by strong HLA-DQB1*0602 association (present in ~98% of NT1 patients versus 30-40% of general population), recent identification of hypocretin neuron-specific antibodies in some patients, and temporal association with H1N1 infection and vaccination.

The most common symptoms of Narcolepsy Type 1 include Excessive daytime sleepiness despite adequate nighttime sleep, Sudden loss of muscle tone triggered by emotion (cataplexy), Sleep paralysis, Hypnagogic/hypnopompic hallucinations, Fragmented nighttime sleep, among others. Narcolepsy Type 1 affects approximately 1 in 2,000 to 3,000 people; often undiagnosed. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Narcolepsy Type 1 from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Medications enhancing central nervous system wakefulness form the foundation of therapy: stimulants including modafinil (first-line), armodafinil, methylphenidate, and amphetamine derivatives manage excessive daytime sleepiness. Sodium oxybate (GHB) addresses both EDS and cataplexy and improves nighttime sleep, and it requires careful dosing and patient education.

Yes. As of October 14, 2026, 4 FDA-approved medicines have a current label that names Narcolepsy Type 1: Orzeyful (oveporexton), first approved in 2026; Wakix (pitolisant); Xyrem (sodium oxybate); and Xywav (calcium, magnesium, potassium, and sodium oxybates). Corticosteroids and immune globulins count once each. The FDA is due to decide on AXS-12 (reboxetine) by May 1, 2027; the FDA calendar page carries the outcome the day it lands.

The exact cause of Narcolepsy Type 1 is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Most patients carry HLA-DQB1*06:02, but it is a risk allele found in many healthy people, not a diagnostic test. The condition affects approximately 1 in 2,000 to 3,000 people; often undiagnosed. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Narcolepsy Type 1. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Most patients carry HLA-DQB1*06:02, but it is a risk allele found in many healthy people, not a diagnostic test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Narcolepsy Type 1 clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Narcolepsy Type 1 clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.